RHHBY - Roche Looking Beyond CAR-T And Other News: The Good Bad And Ugly Of Biopharma
Of all the new science coming in through ASH 2019, one of the most important abstracts is this one from Roche (RHHBY).
Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines
If current excitement surrounding the ASH is all about CAR-T, then this abstract stands out because it is looking at patients who have already gone through a CAR-T therapy and have either relapsed or were resistant to it. So, mosunetuzumab